Aurobindo receives FDA nod for generic Uloric
Febuxostat tablets are indicated for the chronic management of hyperuricemia in patients with gout.
Aurobindo has received the Food and Drug Administration’s permission for febuxostat tablets, 40 mg and 80 mg, which are the generic of Takeda’s Uloric.
[Read more: Aurobindo gets FDA nod for 3 generics]
Febuxostat tablets are indicated for the chronic management of hyperuricemia in patients with gout.
Febuxostat tablets had a market value of approximately $28 million for the 12 months ending August 2023, per IQVIA.